190 related articles for article (PubMed ID: 28480833)
41. Colloidal carriers: a rising tool for therapy of tuberculosis.
Gupta S; Kumar P; Gupta MK; Vyas S
Crit Rev Ther Drug Carrier Syst; 2012; 29(4):299-53. PubMed ID: 22746187
[TBL] [Abstract][Full Text] [Related]
42. Alginate nanoparticles as antituberculosis drug carriers: formulation development, pharmacokinetics and therapeutic potential.
Ahmad Z; Pandey R; Sharma S; Khuller GK
Indian J Chest Dis Allied Sci; 2006; 48(3):171-6. PubMed ID: 18610673
[TBL] [Abstract][Full Text] [Related]
43. Nanostructured Therapeutic Carriers for Tuberculosis Treatment: Approaches & Challenges.
Ullah Z; Athar MT; Samad A
Recent Pat Antiinfect Drug Discov; 2017; 12(2):128-137. PubMed ID: 28990537
[TBL] [Abstract][Full Text] [Related]
44. Assuring bioavailability of fixed-dose combinations of anti-tuberculosis medications. A joint statement of the International Union Against Tuberculosis and Lung Diseases and the World Health Organization.
Int J Tuberc Lung Dis; 1999 Nov; 3(11 Suppl 3):S282-3. PubMed ID: 10593704
[No Abstract] [Full Text] [Related]
45. Pharmacodynamics and pharmacokinetics of SQ109, a new diamine-based antitubercular drug.
Jia L; Tomaszewski JE; Hanrahan C; Coward L; Noker P; Gorman G; Nikonenko B; Protopopova M
Br J Pharmacol; 2005 Jan; 144(1):80-7. PubMed ID: 15644871
[TBL] [Abstract][Full Text] [Related]
46. [Anti-tuberculosis drugs].
Doi N
Nihon Rinsho; 2007 Feb; 65 Suppl 2 Pt. 1():367-74. PubMed ID: 17455647
[No Abstract] [Full Text] [Related]
47. Current Approaches and Future Prospects of Nanomedicine in Tuberculosis Therapy.
Athar MT; Ullah Z
Recent Pat Antiinfect Drug Discov; 2017; 12(2):120-127. PubMed ID: 28443511
[TBL] [Abstract][Full Text] [Related]
48. Chemotherapeutic potential of alginate-chitosan microspheres as anti-tubercular drug carriers.
Pandey R; Khuller GK
J Antimicrob Chemother; 2004 Apr; 53(4):635-40. PubMed ID: 14998985
[TBL] [Abstract][Full Text] [Related]
49. Nanocarriers for respiratory diseases treatment: recent advances and current challenges.
Trapani A; Gioia SD; Castellani S; Carbone A; Cavallaro G; Trapani G; Conese M
Curr Top Med Chem; 2014; 14(9):1133-47. PubMed ID: 24678708
[TBL] [Abstract][Full Text] [Related]
50. Azole antifungals as novel chemotherapeutic agents against murine tuberculosis.
Ahmad Z; Sharma S; Khuller GK
FEMS Microbiol Lett; 2006 Aug; 261(2):181-6. PubMed ID: 16907718
[TBL] [Abstract][Full Text] [Related]
51. Drug delivery for tuberculosis: is inhaled therapy the key to success?
Traini D; Young PM
Ther Deliv; 2017 Oct; 8(10):819-821. PubMed ID: 28944739
[No Abstract] [Full Text] [Related]
52. 2 Receptor Specific Ligand Conjugated Nanocarriers: An Effective Strategy for Targeted Therapy of Tuberculosis.
Prabhu P; Fernandes T; Damani M; Chaubey P; Narayanan S; Sawarkar S
Curr Drug Deliv; 2022; 19(8):830-845. PubMed ID: 34915835
[TBL] [Abstract][Full Text] [Related]
53. Lung specific stealth liposomes as antitubercular drug carriers in guinea pigs.
Pandey R; Sharma S; Khuller GK
Indian J Exp Biol; 2004 Jun; 42(6):562-6. PubMed ID: 15260105
[TBL] [Abstract][Full Text] [Related]
54. Spray-dried particles as pulmonary delivery system of anti-tubercular drugs: design, optimization, in vitro and in vivo evaluation.
Garg T; Goyal AK; Rath G; Murthy RS
Pharm Dev Technol; 2016 Dec; 21(8):951-960. PubMed ID: 26334961
[TBL] [Abstract][Full Text] [Related]
55. Development and characterization of spray-dried porous nanoaggregates for pulmonary delivery of anti-tubercular drugs.
Kaur R; Garg T; Malik B; Gupta UD; Gupta P; Rath G; Goyal AK
Drug Deliv; 2016; 23(3):882-7. PubMed ID: 24870203
[TBL] [Abstract][Full Text] [Related]
56. [Treatment of tuberculosis].
Covi M; Velluti G
Medicina (Firenze); 1989; 9(4):355-74. PubMed ID: 2517449
[TBL] [Abstract][Full Text] [Related]
57. Cure of tuberculosis using nanotechnology: An overview.
Kerry RG; Gouda S; Sil B; Das G; Shin HS; Ghodake G; Patra JK
J Microbiol; 2018 May; 56(5):287-299. PubMed ID: 29721825
[TBL] [Abstract][Full Text] [Related]
58. Bioavailability and delivery of nutraceuticals using nanotechnology.
Huang Q; Yu H; Ru Q
J Food Sci; 2010; 75(1):R50-7. PubMed ID: 20492195
[TBL] [Abstract][Full Text] [Related]
59. Therapeutic efficacy of Poly(DL-lactide-Co-Glycolide)-encapsulated antitubercular drugs against Mycobacterium tuberculosis infection induced in mice.
Dutt M; Khuller GK
Antimicrob Agents Chemother; 2001 Jan; 45(1):363-6. PubMed ID: 11121000
[TBL] [Abstract][Full Text] [Related]
60. Development and characterization of ligand-appended liposomes for multiple drug therapy for pulmonary tuberculosis.
Bhardwaj A; Kumar L; Narang RK; Murthy RS
Artif Cells Nanomed Biotechnol; 2013 Feb; 41(1):52-9. PubMed ID: 22889361
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
